Revolution Medicines (RVMD) EBT Margin (2019 - 2023)

Revolution Medicines' EBT Margin history runs 5 years deep, the most recent figure standing at 21724.26% for Q4 2023.

• On a quarterly basis, EBT Margin fell 2135485.0% year-over-year to 21724.26% in Q4 2023; TTM through Sep 2024 was 76377.09%, a 7509565.0% decrease from a year earlier, with the FY2023 full-year figure at 3798.71%, down 309457.0% from the prior year.
• EBT Margin fell to 21724.26% in Q4 2023 per RVMD's latest filing, from 2570.55% in the prior quarter.
• Across five years, EBT Margin topped out at 76.95% in Q1 2019 and bottomed at 21724.26% in Q4 2023.
• The 5-year median for EBT Margin is 386.72% (2020), against an average of 1945.8%.
• Across the five-year window, EBT Margin surged 261449 bps in 2022 and plunged 2135485 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 156.92% in 2019, then tumbled by 146 bps to 386.72% in 2020, then tumbled by 44 bps to 556.83% in 2021, then jumped by 34 bps to 369.41% in 2022, then sank by 5781 bps to 21724.26% in 2023.
• Per Business Quant, the three latest RVMD EBT Margin figures stand at 21724.26% (Q4 2023), 2570.55% (Q2 2023), and 970.89% (Q1 2023).